Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046676 | 0.96 | HRH3 (0.47) | HRH3GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL20046465 | 0.89 | HRH3 (0.51) | HRH3GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL23960996 | 0.89 | GPR119 (0.52) | GPR119ALDH1A1DDB1CRBNSCD | |
| SCHEMBL30893463 | 0.89 | GPR119 (0.52) | GPR119ALDH1A1DDB1CRBNSCD | |
| SCHEMBL27169461 | 0.86 | SCD (0.45) | GPR119ALDH1A1DDB1CRBNSCD | |
| SCHEMBL20076058 | 0.85 | GPR119 (0.47) | HRH3GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL20046423 | 0.84 | SCD (0.46) | HRH3GPR119ALDH1A1DDB1CRBN | |
| SCHEMBL20076052 | 0.83 | GPR119 (0.46) | GPR119ALDH1A1SCD | |
| SCHEMBL25208908 | 0.82 | HRH3 (0.71) | HRH3GPR119 | |
| SCHEMBL31605540 | 0.82 | GPR119 (0.53) | GPR119ALDH1A1DDB1CRBNSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018071606-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3537/4885GPR119 887/4885OPRM1 1832/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3553/4885GPR119 866/4885OPRM1 1885/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3553/4885GPR119 866/4885OPRM1 1885/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3537/4885GPR119 887/4885OPRM1 1832/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3553/4885GPR119 866/4885OPRM1 1885/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3553/4885GPR119 866/4885OPRM1 1885/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3537/4885GPR119 887/4885OPRM1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.